190 related articles for article (PubMed ID: 9331714)
1. Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients.
Norrby-Teglund A; Low DE; McGeer A; Kotb M
Adv Exp Med Biol; 1997; 418():563-6. PubMed ID: 9331714
[No Abstract] [Full Text] [Related]
2. Superantigens and streptococcal toxic shock syndrome.
Proft T; Sriskandan S; Yang L; Fraser JD
Emerg Infect Dis; 2003 Oct; 9(10):1211-8. PubMed ID: 14609454
[TBL] [Abstract][Full Text] [Related]
3. Dilemmas in the treatment of invasive Streptococcus pyogenes infections.
Stevens DL
Clin Infect Dis; 2003 Aug; 37(3):341-3. PubMed ID: 12884157
[No Abstract] [Full Text] [Related]
4. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome.
Darenberg J; Söderquist B; Normark BH; Norrby-Teglund A
Clin Infect Dis; 2004 Mar; 38(6):836-42. PubMed ID: 14999628
[TBL] [Abstract][Full Text] [Related]
5. Detection of circulating bacterial superantigen and lymphotoxin-alpha in patients with streptococcal toxic-shock syndrome.
Sriskandan S; Moyes D; Cohen J
Lancet; 1996 Nov; 348(9037):1315-6. PubMed ID: 8909404
[No Abstract] [Full Text] [Related]
6. Streptococcal toxic shock syndrome (STSS). An update: a roundtable presentation.
Holm SE; Köhler W; Kaplan EL; Schlievert PM; Alouf JE; Stevens DL; Kotb M
Adv Exp Med Biol; 1997; 418():193-9. PubMed ID: 9331631
[No Abstract] [Full Text] [Related]
7. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.
Norrby-Teglund A; Kaul R; Low DE; McGeer A; Newton DW; Andersson J; Andersson U; Kotb M
J Immunol; 1996 Apr; 156(8):3057-64. PubMed ID: 8609429
[TBL] [Abstract][Full Text] [Related]
8. Novel superantigens from streptococcal toxic shock syndrome Streptococcus pyogenes isolates.
Newton D; Norrby-Teglund A; McGeer A; Low DE; Schlievert PM; Kotb M
Adv Exp Med Biol; 1997; 418():525-9. PubMed ID: 9331707
[No Abstract] [Full Text] [Related]
9. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review.
Perez CM; Kubak BM; Cryer HG; Salehmugodam S; Vespa P; Farmer D
Am J Med; 1997 Jan; 102(1):111-3. PubMed ID: 9209207
[No Abstract] [Full Text] [Related]
10. Application of a rat model of streptococcal shock to evaluate on-line hemoperfusion and removal of circulating superantigens.
Fenwick P; Ryan C; Sriskandan S; Cohen J
Crit Care Med; 2003 Jan; 31(1):171-8. PubMed ID: 12545012
[TBL] [Abstract][Full Text] [Related]
11. Relative avidities of human immunoglobulin G antibodies for streptococcal pyrogenic exotoxins A and B.
Mascini EM; Jansze M; Verhoef J; van Dijk H
Clin Diagn Lab Immunol; 1999 Nov; 6(6):977-80. PubMed ID: 10548596
[TBL] [Abstract][Full Text] [Related]
12. Invasive group A streptococcal disease. Association with a lack of anti-exotoxin antibodies.
Mascini EM; Hazenberg MM; van Dalen A; Verhoef-Verhage LA; van Leeuwen NJ; Verhoef J; van Dijk H
Adv Exp Med Biol; 1997; 418():921-2. PubMed ID: 9331799
[No Abstract] [Full Text] [Related]
13. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy.
Norrby-Teglund A; Basma H; Andersson J; McGeer A; Low DE; Kotb M
Clin Infect Dis; 1998 Mar; 26(3):631-8. PubMed ID: 9524835
[TBL] [Abstract][Full Text] [Related]
14. T cell activation and cytokine release in streptococcal toxic shock-like syndrome.
Nadal D; Lauener RP; Braegger CP; Kaufhold A; Simma B; Lütticken R; Seger RA
J Pediatr; 1993 May; 122(5 Pt 1):727-9. PubMed ID: 8496751
[TBL] [Abstract][Full Text] [Related]
15. Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome.
Eriksson BK; Andersson J; Holm SE; Norgren M
J Infect Dis; 1999 Aug; 180(2):410-8. PubMed ID: 10395857
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro detection of a superantigenic toxin Vbeta signature in two forms of streptococcal toxic shock syndrome.
Thomas D; Perpoint T; Dauwalder O; Lina G; Floccard B; Richard JC; Bouvet A; Peyramond D; Allaouchiche B; Chidiac C; Vandenesch F; Etienne J; Ferry T
Eur J Clin Microbiol Infect Dis; 2009 Jun; 28(6):671-6. PubMed ID: 19020908
[TBL] [Abstract][Full Text] [Related]
17. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome.
Stevens DL
Clin Infect Dis; 1998 Mar; 26(3):639-41. PubMed ID: 9524836
[No Abstract] [Full Text] [Related]
18. Streptococcal DNase B is immunologically identical to superantigen SpeF but involves separate domains.
Eriksson A; Eriksson B; Holm SE; Norgren M
Clin Diagn Lab Immunol; 1999 Jan; 6(1):133-6. PubMed ID: 9874677
[TBL] [Abstract][Full Text] [Related]
19. Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections.
Basma H; Norrby-Teglund A; McGeer A; Low DE; El-Ahmedy O; Dale JB; Schwartz B; Kotb M
Infect Immun; 1998 May; 66(5):2279-83. PubMed ID: 9573118
[TBL] [Abstract][Full Text] [Related]
20. Culture-negative severe septic shock: indications for streptococcal aetiology based on plasma antibodies and superantigenic activity.
Norrby-Teglund A; Berdal JE
Scand J Infect Dis; 2001; 33(8):634-7. PubMed ID: 11525365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
